Compare Ginkgo Bioworks Holdings Inc (DNA) vs Starbucks Corp (SBUX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Starbucks Corp — how do they compare? Ginkgo Bioworks Holdings Inc trades at $13.12 (market cap $763.64M), while Starbucks Corp trades at $91.76 (market cap $106.26B). The key difference: Starbucks Corp is far larger — about 139.1× Ginkgo Bioworks Holdings Inc's market cap, and Starbucks Corp pays a 2.7% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and Starbucks Corp for 190 Days on average.
| DNA | SBUX | |
|---|---|---|
Market Cap | $763.64M | $106.26B |
Volume | 3,204,177 | 30,248,434 |
Sector | Health | Consumer Cyclical |
52-Week High | $15.83 | $108.55 |
52-Week Low | $5.48 | $78.46 |
Typical Hold Time | 7 Days | 190 Days |
Enterprise Value | $865.59M | $125.08B |
Dividend Yield | — | 2.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $13.04, up 13.69% in the last session, with a bullish technical signal from moving averages. The company maintains strong gross margins at 68.04% but faces significant losses with a -219.6% net income margin. Recent developments include a $17.5M ARPA-H subcontract for RNA medicine manufacturing and partnerships expanding genetic testing distribution.
While technical momentum appears positive, fundamental challenges persist with substantial cash burn and declining revenue projections. Analyst sentiment is divided equally between buy, hold, and sell ratings. Investment opportunity lies in the company's strategic partnerships and government contracts, balanced against ongoing profitability concerns and competitive pressures in biotech.
Starbucks (SBUX) trades at $91.66, down 2.05% amid a bearish technical outlook with support at $89 and resistance at $92. The company reported mixed quarterly results with Q2 2026 EPS beating expectations at $0.85 vs. $0.66, but Q4 2025 missed at $0.56. Recent news highlights store closures and restructuring charges of approximately $300 million as part of a strategic turnaround. Revenue growth remains modest at $37.18B for 2025, with net income margin at 5.17%.
The stock presents a cautious opportunity with analyst consensus price target of $115.50 implying 26% upside, though high P/E of 53.88 raises valuation concerns. Key risks include execution of store optimization, labor relations, and geopolitical tensions in China. Institutional sentiment is divided with 47% buy ratings, but technical indicators signal near-term pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Starbucks Corp
Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →
